Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Praxis Precision Medicines
Biotech
Praxis' epilepsy drug hits in phase 2, sparking stock rise
Praxis linked the high dose of PRAX-628 to a 100% complete response rate to clear the path for a larger study in the second half of the year.
Nick Paul Taylor
Mar 26, 2024 10:24am
Praxis share price halved by tremor fail but still plans phase 3
Mar 3, 2023 9:05am
Praxis ends year on high with $100M biobucks UCB deal
Dec 14, 2022 5:29am
Praxis acts fast as depression drug flunks late-phase test
Jun 6, 2022 9:40am
FDA slaps clinical hold on Praxis’ leading epilepsy candidate
Apr 29, 2022 12:31pm
Praxis clinches $190M IPO, surpassing even its upsized target
Oct 15, 2020 2:46pm